MedPath

Effect of NSAIDs in H.pylori treatment

Phase 2
Conditions
Helicobacter pylori.
Helicobacter pylori [H.pylori] as the cause of diseases classified
Registration Number
IRCT201204059256N2
Lead Sponsor
Isfahan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
172
Inclusion Criteria

Inclusion criterion: patients with H.pylori infection. Exclusion criteria: previous treatment for H. pylori infection; use of PPI (proton pomp inhibitors) during 2 weeks and/or antibiotics during 4 weeks before the study; having peptic ulcer, GERD, gastrointestinal malignancy, previous gastro-oesophageal surgery; severe concomitant cardiovascular, hypertention, respiratory or endocrine diseases, clinically significant renal or hepatic disease, haematological disorders; any other clinically significant medical conditions that could increase risk; history of allergy to any of the drug used in the study; pregnancy or lactation; alcohol abuse; drug addiction; severe neurological or psychiatric disorders and contraindication of consumption of NSAID and long-term use of corticosteroids or anti-inflammatory drugs

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Helicobacter pylori eradication. Timepoint: 4-6 weeks after completion of treatment. Method of measurement: stool antigen assay for H. pylori.
Secondary Outcome Measures
NameTimeMethod
Symptoms improvement. Timepoint: 8-10 weeks after treatment. Method of measurement: glasgow dyspepsia severity questionnaire.
© Copyright 2025. All Rights Reserved by MedPath